CAR-NK Cells + Belzutifan for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment combining CAR-engineered NK cells (a type of immunotherapy) with a medication called belzutifan for pancreatic cancer. The researchers aim to determine the safety of this combination and identify the best dose for future studies. This trial targets individuals with pancreatic cancer unresponsive to previous treatments like FOLFIRINOX or gemcitabine, who are willing to undergo certain procedures and tests. Participants will receive part of the treatment in the hospital and continue taking belzutifan at home. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, you must be at least 5 half-lives from your last cytotoxic chemotherapy before starting the trial, and you cannot be on certain treatments like live vaccines or investigational agents close to the trial start.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that TROP2 CAR-engineered NK cells could help treat cancers like pancreatic and ovarian. Early studies found these cells effective and safe, as they can kill cancer cells without causing major problems.
Belzutifan, another part of the trial, has been used in patients with Von Hippel-Lindau (VHL) disease and demonstrated a good safety record over long-term use. Some patients needed dose adjustments, but the treatment remained manageable. Its approval for other conditions further indicates its safety.
In summary, both treatments in this trial have demonstrated safety in previous studies. The TROP2 CAR-NK cells and belzutifan have been well-tolerated, with manageable side effects.12345Why are researchers excited about this trial's treatments?
Researchers are excited about the combination of CAR-NK cells and Belzutifan for pancreatic cancer because it introduces a novel approach to treatment. Unlike traditional therapies like chemotherapy or targeted drugs, this treatment uses engineered immune cells, specifically TROP2 CAR/IL-15 TGFBR2 KO NK cells, to target and destroy cancer cells more effectively. Additionally, Belzutifan is an oral medication that can be self-administered at home, potentially making it more convenient for patients compared to standard intravenous treatments. This combination has the potential to enhance the body's natural immune response against cancer while offering a more patient-friendly treatment regimen.
What evidence suggests that this trial's treatments could be effective for pancreatic cancer?
Research has shown that TROP2 CAR-engineered NK cells, which participants in this trial will receive, could effectively fight cancers like pancreatic cancer. These cells are specially designed to find and destroy cancer cells by recognizing a protein called TROP2 on their surface. Early studies suggest they can help shrink tumors in pancreatic and ovarian cancers.
Participants in this trial will also receive Belzutifan, which has shown promising results in treating pancreatic growths related to von Hippel–Lindau disease. Specifically, 84% of patients experienced tumor shrinkage or disappearance.
Together, these treatments in this trial offer hope for managing hard-to-treat pancreatic cancers.46789Who Is on the Research Team?
Maria Morelli, MD,PHD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for adults over 18 with pancreatic cancer that's advanced and can't be removed by surgery. They should have tried certain chemotherapies without success, be in good physical shape (ECOG 0 or 1), and not planning to get pregnant. Participants must agree to use contraception, have a port placed in their belly for treatment delivery, and consent to long-term follow-up.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive TROP2 CAR/IL-15 TGFBR2 KO NK cells intraperitoneally and intravenously in combination with oral belzutifan
Follow-up
Participants are monitored for safety, effectiveness, and quality of life after treatment
Long-term follow-up
Participants are monitored for progression-free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- TROP2 CAREngineered Cord Blood-Derived NK Cells
Trial Overview
The study tests TROP2 CAR/IL-15 TGFBR2 KO NK cells given into the abdomen combined with an oral drug called belzutifan for recurrent or spreading pancreatic cancer. It aims to find a safe dose and see how well patients tolerate this new therapy.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Treatment will be administered on an inpatient basis for lymphodepleting therapy, cell infusion and first doses of belzultifan, and on an outpatient basis after patients are dismissed from the hospital and continue self-administering belzultifan at home.
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Citations
Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion ...
Belzutifan was shown to have durable antitumor activity and a manageable safety profile in VHL disease–associated pNETs and non-pNET lesions such as serous ...
Real-world outcomes and toxicity with belzutifan in the ...
Conclusions: Our real-world outcomes demonstrate that belzutifan is effective in treatment of VHL disease and generally being well-tolerated.
3.
aacrjournals.org
aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-23-2592/742954/p/Belzutifan-for-von-Hippel-Lindau-DiseaseBelzutifan for von Hippel–Lindau Disease: Pancreatic Lesion ...
Median follow-up was 37.8 months (range, 36.1–46.1). ORR was 84% [51/61; 17 complete responses (CR)] in pancreatic lesions and 91% (20/22; 7 CRs) in pNETs.
4.
onclive.com
onclive.com/view/belzutifan-maintains-high-durable-responses-in-vhl-disease-associated-neoplasms-at-5-yearsBelzutifan Maintains High, Durable Responses in VHL ...
Belzutifan maintained a 70% ORR in VHL-associated RCC, with a 76.2% estimated 48-month DOR, highlighting its long-term efficacy. · The trial ...
European medicines agency review of belzutifan (Welireg) for ...
For VHL-RCC the overall response rate (ORR) was 67.2%, with a median duration of response not reached.
Real-world outcomes and safety in patients with VHL ...
Our real-world outcomes analysis of patients with VHL-associated tumors who are treated with Belzutifan shows an improved objective response.
Long-term Safety and Efficacy of Belzutifan in Von Hippel ...
Treatment interruption happened in 80% of the patients. The dose reduction was needed in 15 (60%) patients, with a median time of 6.8 months, ...
P17.34.B BELZUTIFAN IN CLINICAL PRACTICE: OUTCOMES ...
Among patients with RCC (n=26), overall response rate (ORR) was 19% and median time to best response (MTBR) was 7.4 months. Five patients had ...
9.
aacrjournals.org
aacrjournals.org/clincancerres/article/30/9/1750/743137/Belzutifan-for-von-Hippel-Lindau-DiseaseBelzutifan for von Hippel–Lindau Disease: Pancreatic Lesion ...
Belzutifan was shown to have durable antitumor activity and a manageable safety profile in VHL disease–associated pNETs and non-pNET lesions such as serous ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.